DexCom's stock narrative has shifted as analysts lower their fair value estimate from $98.40 to $84.96, marking a significant downward revision in the price target. This adjustment is primarily driven ...

DexCom (DXCM) just received FDA clearance for Smart Basal, a new device designed to help adults with Type 2 diabetes optimize their insulin dosing using personalized, real-time sensor data. This ...

Rising costs and complex care make diabetes a daily challenge. Local patient and pharmacy expert share strategies, struggles, ...

Shilpa Pharma Lifesciences Limited, a material subsidiary of Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED), has been awarded the prestigious Gold Medal by EcoVadis, the world's most trusted ...

Riva Medical, Inc., a privately held, development stage medical device company based in Minneapolis, and NuXcel spinoff, announced the closing of its initial financing led by F-Prime, with ...

The S&P 1500 Health Care Index gained 1.9% in September, underperforming the S&P 500, which advanced 3.7%. Read more here.

Q3 2025 Management View CEO Ashley McEvoy welcomed Flavia Pease as the new CFO and announced Eric Benjamin's promotion to COO and the appointment of Manoj Raghunandanan as Chief Growth Officer. McEvoy ...

SAN DIEGO (AP) — SAN DIEGO (AP) — DexCom Inc. (DXCM) on Thursday reported third-quarter net income of $283.8 million. The San Diego-based company said it had net income of 70 cents per share. Earnings ...

Pre-earnings options volume in DexCom (DXCM) is 5.0x normal with calls leading puts 19:6. Implied volatility suggests the market is anticipating a move near 11.3%, or $7.76, after results are released ...

LOS ANGELES, Nov. 3, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DexCom, Inc. ("DexCom" or "the Company ...

Dexcom Inc. executives may have thought a $30 million beat of the consensus estimates for third quarter revenue and 20% growth year-over-year provided a treat to shareholders, but investors seemed to ...

According to Precedence Research, the global glucose biosensors market size will grow from USD 10.71 billion in 2025 to nearly USD 23.08 billion by 2034, with an expected CAGR of 8.91% from 2025 to ...